Le Lézard
Classified in: Business

Thunder Bridge Acquisition, Ltd. Announces Separate Trading of its Class A Ordinary Shares and Warrants, Commencing July 17, 2018


NEW YORK, July 13, 2018 /PRNewswire/ -- Thunder Bridge Acquisition, Ltd. (the "Company") (NASDAQ: TBRGU) announced today that, commencing on July 17, 2018, the holders of the units sold in the Company's initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units. Units that are not separated will continue to trade on The NASDAQ Capital Market ("NASDAQ") under the symbol "TBRGU." The Class A ordinary shares and the warrants that are separated are expected to trade on NASDAQ under the symbols "TBRG" and "TBRGW," respectively. 

The units were initially offered by the Company in an underwritten offering.  Cantor Fitzgerald & Co. acted as sole book-running manager and Chardan acted as lead manager of the offering.

Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants.

A registration statement relating to the units and the underlying securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on June 18, 2018.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A copy of the final prospectus relating to the offering may be obtained for free by visiting the SEC website at www.sec.gov.  Alternatively, a copy of the prospectus related to this offering may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 5th Floor New York, New York 10022; Email: [email protected].

Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the Company's initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Gary A. Simanson
202.431.0507
[email protected]

SOURCE Thunder Bridge Acquisition, Ltd.


These press releases may also interest you

at 16:25
Xylem Inc. , a leading global water technology company dedicated to solving the world's most challenging water issues, will release its first quarter 2024 results at 6:55 a.m. (ET) on Thursday, May 2, 2024. At 9:00 a.m. (ET), Xylem's senior...

at 16:25
Amerant Bancorp Inc. ("Amerant" or the "Company"), today announced it will release first quarter 2024 earnings results on Wednesday, April 24, 2024 after the market closes. Once released, investors may access Amerant's earnings results at...

at 16:25
Fortive Corporation ("Fortive") today announced that it will webcast its earnings conference call for the first quarter 2024 on Wednesday, April 24, 2024 beginning at 12:00 p.m. ET and lasting approximately 1 hour. The call and an accompanying...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
Intellinetics, Inc. , a digital transformation solutions provider, announced financial results for the three and 12 months ended December 31, 2023. 2023 Fourth Quarter Financial Highlights Total Revenue increased 3.8% over the same period in...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...



News published on and distributed by: